Suppr超能文献

肺移植受者中 SARS-CoV-2 感染和康复的临床病程。

Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients.

机构信息

Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

出版信息

Transpl Infect Dis. 2022 Dec;24(6):e13967. doi: 10.1111/tid.13967. Epub 2022 Nov 8.

Abstract

BACKGROUND

Reports on outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in lung transplant recipients remain limited.

METHODS

We performed a single-center, observational study of outcomes in lung transplant recipients diagnosed with SARS-CoV-2 between 5/1/2020 and 3/15/2022 that were followed for a median of 123 days. We analyzed changes in spirometry, acute lung allograft dysfunction (ALAD) incidence, hospitalization, mechanical ventilation needs, secondary infection, and survival.

RESULTS

In our cohort of 336 patients, 103 developed coronavirus disease (COVID) (27 pre-Delta, 20 Delta, and 56 Omicron-era). Twenty-five patients (24%) required hospitalization and 10 patients ultimately died (10%). Among 85 survivors who completed ambulatory spirometry, COVID-19 did not alter change in forced expiratory volume in 1 s (FEV ) or forced vital capacity (FVC) over time compared to the preceding 6 months. The pre-COVID FEV change was -0.05 ml/day (IQR -0.50 to 0.60) compared to -0.20 ml/day (IQR -1.40 to 0.70) post-COVID (p = .16). The pre-COVID change in FVC was 0.20 ml/day (IQR -0.60 to 0.70) compared to 0.05 ml/day (IQR -1.00 to 1.10) post-COVID (p = .76). Although the cohort overall had stable lung function, 33 patients (39%) developed ALAD or accelerated chronic lung allograft dysfunction (FEV decline >10% from pre-COVID baseline). Nine patients (35%) with ALAD recovered lung function. Within 3 months of acute COVID infection, 18 patients (17%) developed secondary infections, the majority being bacterial pneumonia. Finally, vaccination with at least two doses of mRNA vaccine was not associated with improved outcomes.

CONCLUSIONS

This study describes the natural history of SARS-CoV-2 infection in a large cohort of lung transplant recipients. Although one third of patients develop ALAD requiring augmented immunosuppression, infection with SARS-CoV-2 is not associated with worsening lung function.

摘要

背景

关于严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染后肺移植受者结局的报告仍然有限。

方法

我们对 2020 年 5 月 1 日至 2022 年 3 月 15 日期间诊断为 SARS-CoV-2 的肺移植受者进行了一项单中心、观察性研究,中位随访时间为 123 天。我们分析了肺功能、急性肺移植物功能障碍(ALAD)发生率、住院、机械通气需求、继发感染和生存率的变化。

结果

在我们的 336 名患者队列中,有 103 名患有冠状病毒病(COVID)(27 名在 Delta 之前,20 名在 Delta 期间,56 名在奥密克戎时期)。25 名患者(24%)需要住院治疗,最终有 10 名患者死亡(10%)。在完成门诊肺量计检查的 85 名幸存者中,与前 6 个月相比,COVID-19 并未改变用力呼气量(FEV )或用力肺活量(FVC)的变化。与 COVID 前相比,COVID 前的 FEV 变化为-0.05ml/天(IQR-0.50 至 0.60),而 COVID 后的变化为-0.20ml/天(IQR-1.40 至 0.70)(p=0.16)。COVID 前 FVC 的变化为 0.20ml/天(IQR-0.60 至 0.70),而 COVID 后为 0.05ml/天(IQR-1.00 至 1.10)(p=0.76)。尽管总体而言,该队列的肺功能稳定,但 33 名患者(39%)发生 ALAD 或加速性慢性肺移植物功能障碍(FEV 从 COVID 前基线下降>10%)。9 名(35%)有 ALAD 的患者恢复了肺功能。在急性 COVID 感染后 3 个月内,18 名患者(17%)发生继发性感染,大多数为细菌性肺炎。最后,至少接种两剂 mRNA 疫苗与改善结局无关。

结论

本研究描述了 SARS-CoV-2 感染在一大群肺移植受者中的自然史。尽管三分之一的患者发生需要增强免疫抑制的 ALAD,但 SARS-CoV-2 感染与肺功能恶化无关。

相似文献

1
Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients.
Transpl Infect Dis. 2022 Dec;24(6):e13967. doi: 10.1111/tid.13967. Epub 2022 Nov 8.
2
Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
Transpl Infect Dis. 2023 Jun;25(3):e14024. doi: 10.1111/tid.14024. Epub 2023 Feb 7.
3
Impact of COVID-19 on long-term lung function in lung transplant recipients: A single-center retrospective cohort study.
Transpl Infect Dis. 2023 Oct;25(5):e14151. doi: 10.1111/tid.14151. Epub 2023 Sep 25.
4
Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation.
Transpl Infect Dis. 2021 Dec;23(6):e13739. doi: 10.1111/tid.13739. Epub 2021 Oct 17.
6
Outcomes of SARS-CoV-2 infection among lung transplant recipients: A single center retrospective study.
Transpl Infect Dis. 2023 Feb;25(1):e14007. doi: 10.1111/tid.14007. Epub 2023 Jan 5.
7
Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
Transpl Immunol. 2022 Jun;72:101599. doi: 10.1016/j.trim.2022.101599. Epub 2022 Apr 4.
9
Efficacy and safety of the SARS-CoV-2 mRNA vaccine in lung transplant recipients: a possible trigger of rejection.
Gen Thorac Cardiovasc Surg. 2023 Apr;71(4):251-257. doi: 10.1007/s11748-022-01887-3. Epub 2022 Oct 26.
10
COVID-19 infection is mild and has minimal impact on lung function in well vaccinated and widely treated lung transplant recipients.
J Heart Lung Transplant. 2024 Jun;43(6):944-953. doi: 10.1016/j.healun.2024.02.1453. Epub 2024 Feb 24.

引用本文的文献

1
Incidence and severity of SARS-CoV-2 infection in lung transplant recipients in the Omicron era.
JHLT Open. 2023 Sep 20;1:100004. doi: 10.1016/j.jhlto.2023.100004. eCollection 2023 Oct.
2
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.
Adv Ther. 2025 Feb;42(2):666-719. doi: 10.1007/s12325-024-03043-0. Epub 2024 Dec 16.
3
A Single-center Experience With >200 Lung Transplant Recipients With COVID-19 Infection.
Transplant Direct. 2024 Aug 29;10(9):e1676. doi: 10.1097/TXD.0000000000001676. eCollection 2024 Sep.
5
COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases.
Viruses. 2024 Apr 29;16(5):709. doi: 10.3390/v16050709.

本文引用的文献

2
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
JAMA Intern Med. 2022 Feb 1;182(2):153-162. doi: 10.1001/jamainternmed.2021.7024.
3
Predictors and outcomes of respiratory failure among lung transplant patients with COVID-19.
Clin Transplant. 2022 Mar;36(3):e14540. doi: 10.1111/ctr.14540. Epub 2021 Dec 5.
4
Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
Transpl Infect Dis. 2022 Feb;24(1):e13759. doi: 10.1111/tid.13759. Epub 2021 Dec 7.
5
COVID-19 in lung transplant recipients-Risk prediction and outcomes.
PLoS One. 2021 Oct 6;16(10):e0257807. doi: 10.1371/journal.pone.0257807. eCollection 2021.
6
Post-infection pulmonary sequelae after COVID-19 among patients with lung transplantation.
Transpl Infect Dis. 2021 Dec;23(6):e13739. doi: 10.1111/tid.13739. Epub 2021 Oct 17.
8
SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients.
J Heart Lung Transplant. 2021 Dec;40(12):1579-1588. doi: 10.1016/j.healun.2021.07.026. Epub 2021 Aug 8.
10
Clinical characteristics, management practices, and outcomes among lung transplant patients with COVID-19.
J Heart Lung Transplant. 2021 Sep;40(9):936-947. doi: 10.1016/j.healun.2021.05.003. Epub 2021 May 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验